Ascension set to take control of Presence Health

Non-profit health company Ascension revealed this week the signing of a non-binding letter of intent for fellow US-based Presence Health to join the company in an acquisition that would make it part of Ascension’s AMITA Health Group.

If the transaction goes ahead, Presence Health’s medical centres and other facilities would be integrated into AMITA Health’s network, a joint venture between Ascension’s Alexian Brothers Health System and Adventist Midwest Health.

“The mission, values and history of Presence Health clearly align well with those of Ascension, as both systems are dedicated to caring for all, with special attention to persons living in poverty and those most vulnerable,” said Ascension’s CEO Anthony Tersigni.

“We believe this will strengthen Catholic healthcare not only in the region but throughout the country as we are all dedicated to delivering personalised, compassionate care.”

See also:

• Philips acquires Spectranetics Corp for $2.16 billion

• Boston, Philadelphia and Cincinnati are the best US states for paediatric healthcare in America

• Penn Medicine to construct $1.5 billion hospital pavilion

With AMITA Health and Presence Health holding similar core principals of faith-based healthcare, the merger would bolster the former’s standings as one of America’s largest hospital systems, something that AMITA Health CEO Mark Frey has expressed his satisfaction towards.

“Since we brought together Alexian Brothers Health System and Adventist Midwest Health to form AMITA Health two years ago, we’ve always looked for opportunities to add like-minded partners with similar values to our system,” he said.

“Bringing Presence Health into Ascension and AMITA Health is a perfect fit and an exciting continuation of our commitment to increase access to quality healthcare in the many communities we serve.”

Through this venture of expansion, AMITA Health will increase citizens’ access to healthcare and deepen specialisation, providing both improved quality and quantity to patients, with the deal expected to complete in early 2018.